New hope for inoperable esophageal cancer? trial tests aggressive drug combo
NCT ID NCT06281886
Summary
This study is testing whether adding a drug called apatinib to a standard treatment plan helps people with advanced esophageal cancer that cannot be removed by surgery. The standard plan involves chemotherapy, immunotherapy, and radiation. Researchers will compare the outcomes of 170 patients who receive the new combination to those who receive the standard plan alone, looking to see if it better controls the cancer and extends life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.